Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Responsibility
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with major unmet needs. Learn More
    • Japanese Encephalitis Vaccine
    • Cholera Vaccine
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development. Learn More
    • Pipeline
    • Lyme Disease – VLA15
    • Chikungunya – VLA1553
    • COVID-19 – VLA2001
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
    • Expanded Access Policy
    • Scientific Publications
  • Investors
    Investors Learn More
    • Events and Presentations
      • Calendar
      • Corporate Presentations
    • Financial & Filings
      • Financial Reports
      • SEC Filings
    • Press Releases
    • Corporate Governance
      • Corporate Governance
      • Corporate Compliance & Ethics
    • Regulated Information
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • General Meetings
      • 2022 Combined General Meeting
      • June 23, 2022 Special Meeting
      • General Meeting Archive
    • Videos and Webcasts
    • FAQ
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • In The News
    • Media Kit
    • Media Contacts
  • Careers
Contact
  • EN
  • FR
  • | DE
Search

In The News

August 16, 2021 PMLive

Valneva’s COVID-19 vaccine to be tested in older people

August 16, 2021 The Scotsman

Covid Scotland: Vaccine company Valneva creates over 200 new positions at West Lothian facility

August 5, 2021 FierceBiotech

Valneva, racing Merck for a priority review voucher, exceeds protection goal in phase 3 chikungunya vaccine trial

August 5, 2021 Pharma Times

Positive Phase III results for Valneva’s chikungunya vaccine

August 5, 2021 Endpoints News

A small vaccine developer favored by the UK government in Covid-19 touts a PhIII first in chikungunya

July 31, 2021 Bloomberg

Ticks and Lyme Disease: Your Questions Answered

July 9, 2021 Homeland Preparedness News

FDA grants breakthrough therapy designation to Valneva’s Chikungunya vaccine candidate

July 5, 2021 www.thenationalnews.com

Valneva, the next-gen Covid-19 vaccine you may not have heard about

June 22, 2021 Time

We Used to Have a Lyme Disease Vaccine. Are We Ready to Bring One Back?

June 3, 2021 FiercePharma

Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
  • Valneva France
Contact
© 2022 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019
We use cookies to improve the functionality and user experience of the website and to analyse the traffic. You can find detailed information in our Privacy Policy.
ACCEPT CHANGE MY PREFERENCES
Privacy & Cookies Policy

Your privacy is important to us

Cookies are very small text files that are stored on your computer when you visit a website. We use cookies for a variety of purposes and to enhance your online experience on our website (for example, to remember your account login details).

You can change your preferences and decline certain types of cookies to be stored on your computer while browsing our website. You can also remove any cookies already stored on your computer, but keep in mind that deleting cookies may prevent you from using parts of our website.

More information

For any queries in relation to our policy on cookies and your choices, please contact us.

To find out more, please visit our Cookies Policy.
Strictly necessary cookies
Always Enabled
These cookies are essential to provide you with services available through our website and to enable you to use certain features of our website.

Without these cookies, we cannot provide you certain services on our website.
Tracking and performance cookies
These cookies are used to collect information to analyze the traffic to our website and how visitors are using our website.

For example, these cookies may track things such as how long you spend on the website or the pages you visit which helps us to understand how we can improve our website site for you.

The information collected through these tracking and performance cookies do not identify any individual visitor.
SAVE & ACCEPT